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Brain glucose sensing, glucokinase and neural control
of metabolism and islet function
E. O. Ogunnowo-Bada, N. Heeley, L. Brochard & M. L. Evans
Wellcome Trust-MRC Institute of Metabolic Science, IMS Metabolic Research Laboratories, University of Cambridge, Cambridge, UK
It is increasingly apparent that the brain plays a central role in metabolic homeostasis, including the maintenance of blood glucose. This is
achieved by various efferent pathways from the brain to periphery, which help control hepatic glucose ﬂux and perhaps insulin-stimulated insulin
secretion. Also, critically important for the brain given its dependence on a constant supply of glucose as a fuel – emergency counter-regulatory
responses are triggered by the brain if blood glucose starts to fall. To exert these control functions, the brain needs to detect rapidly and
accurately changes in blood glucose. In this review, we summarize some of the mechanisms postulated to play a role in this and examine
the potential role of the low-afﬁnity hexokinase, glucokinase, in the brain as a key part of some of this sensing. We also discuss how these
processes may become altered in diabetes and related metabolic diseases.
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Introduction
In health, blood glucose is maintained within relatively narrow
limits despite a variety of potential perturbations. This control is
effected by co-ordinated homeostatic physiological responses
in pancreas, liver and skeletal muscle. Over recent years, it
has become apparent that the brain also plays a pivotal role
in controlling peripheral energy and metabolic homeostasis,
including the control of blood glucose. Teleologically, this
would appear to be logical given the dependence of the brain
on a constant uninterrupted supply of glucose from the blood
stream to fuel metabolism and support function.
A key part of this homeostatic process is that the brain needs
to detect rapidly and accurately changes in blood glucose.
Specialized brain fuel sensors monitor changes in ambient
glucose. Importantly, in addition to local fuel sensing, the brain
also receives information about changes in blood glucose from
a number of other sources. Levels of circulating hormones such
as insulin and glucagon respond to changes in blood glucose.
Afferent neural inputs from peripheral sites – for example,
vagal afferents from hepatic portal glucose sensors also feed in
information.
The brain then utilizes this information to exert central
and strategic control on a number of aspects of metabolism
and energy balance. Triggering of counter-regulatory responses
to falling glucose is perhaps the most obvious exemplar, but
autonomic outflow from the brain also helps control hepatic
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glucose flux and facilitates glucose-stimulated insulin release
from the pancreas.
A number of candidate mechanisms and indeed brain areas
and cell types have been postulated as being important for
local brain glucose sensing. We review below the current data,
focusing particularly on the evidence for a role for the low-
affinity hexokinase, glucokinase, in brain. In this review, we
will: (i) first provide an outline of the evidence that brain
glucose sensing is important for glucose homeostasis, (ii) give
an overview of brain glucose-sensing mechanisms including
those using glucokinase, (iii) then describe the current data
supporting a role for brain glucokinase in the central control of
glucose homeostasis and (iv) discuss how these processes may
become altered in diabetes and related metabolic disorders.
Brain Glucose Sensing and Hypoglycaemia
The best-established homeostatic process that involves brain
glucose sensing is the defensive response to hypoglycaemia. In
health, a fall in blood glucose triggers a series of physiological
responses aimed at limiting the fall and restoring euglycaemia
(see Ref. [1] for review). Counter-regulatory neurohumoral
responses include the cessation of endogenous insulin release
followed by release of glucagon, catecholamines (including
adrenaline from the adrenal medulla and increased autonomic
outflow with a rise in circulating noradrenaline from spillover
from sympathetic synapses), growth hormone and triggering of
the hypophyseal–adrenal axis [adrenocorticotrophin (ACTH)
and glucocorticoids]. These changes tend to limit glucose
utilization and attempt to increase hepatic glucose output,
not only by hormonal effects, but also probably through
direct autonomic innervation of the liver. Counter-regulatory
neurohumoral changes are associated with the generation of
‘adrenergic’ warning symptoms such as sweating, shaking and
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heart palpitations. Importantly, hunger is also stimulated and
consequent feeding will help restore and maintain euglycaemia.
If blood glucose falls sufficiently low, cognitive function
starts to become impaired with a number of cognitive domains
being affected – particularly those requiring attention, speed
of response and judgement. Neuroglycopenic symptoms – for
example, tingling of lips and irritability – are probable
consequences of a fall in brain fuel. Because the brain is so
dependent on circulating glucose to fuel metabolism and sup-
port function, it makes teleological sense for brain areas to be
involved in monitoring blood glucose and triggering defences.
Evidence for a role for brain sensors in responses to
hypoglycaemia came originally from studies using selective
catheterization in dogs. Using this methodology, maintaining
brain glucose during systemic hypoglycaemia resulted in
a reduced neurohumoral reaction to the hypoglycaemic
challenge, suggesting that it was the fall in glucose within the
brain that triggered the processes leading to counter-regulation
[2,3]. Elegant rat studies suggested an important role for
the ventromedial nucleus of the hypothalamus (VMN), with
local delivery of 2-deoxy glucose (2DG) to induce glucopenia,
stimulating a counter-regulatory response. Also in keeping
with a role for the VMN, lesioning of the VMN by stero-
tactic injection of ibotenic acid reduced counter-regulation.
Similarly, maintenance of VMN glucose by locally delivered
glucose during hypoglycaemia reduced counter-regulation
[4–6]. Supporting a role for the brain stem, studies using 2DG
or the alternative glucoprivic agent, 5-thioglucose, showed
that hindbrain sensing of glucopenia was important [7–9].
Consistent with these data, a number of studies using more
contemporary experimental manipulations have confirmed
that a number of sites in both hypothalamus and brain stem
are critical for triggering counter-regulatory responses. For
example, mice lacking vesicular transporters for glutamate in
VMN steroidogenic factor 1 (SF1) SF1 neurones have defective
glucagon response to hypoglycaemia [10].
Importantly, in addition to brain sensing of hypoglycaemia,
glucose sensors from the periphery, particularly portal vein
sensors, may also play a significant role, especially for slowly
developing hypoglycaemia [11–13], probably contributing
information via vagal afferents into the dorsal vagal complex
in the brain stem [14].
In diabetes, aggressive blood glucose lowering therapy
increases risk of overshooting such that counter-regulatory
responses become critical to preventing and/or limiting
hypoglycaemia and restoring normal glucose. Described later,
some patients develop deficits in counter-regulatory defences,
putting them at greater risk of severe hypoglycaemia. A better
understanding of the physiology of counter-regulation includ-
ing how hypoglycaemia is sensed – whether glucokinase-
mediated or not – and how these responses may become
altered in diabetes could allow prevention of problematic
hypoglycaemia.
Brain Glucose Sensing and Pancreatic
Insulin Secretion
Over the last decade, the role of the brain in controlling
hepatic glucose flux, at least in rodent models, has been
firmly established. In particular, there is a clear circuitry from
the hypothalamus via vagal outflow to control glycaemia in
response to locally detected changes in nutrients including glu-
cose, and the circuitry has been well-described elsewhere [15].
A similar role for the brain in modulating glucose-stimulated
insulin secretion has also been suggested. Although the pancreas
and indeed isolated islets and β-cells are capable of detecting
changes in blood glucose and altering insulin secretion
appropriately, the pancreas, including islets, is richly innervated
by sympathetic (splanchnic), parasympathetic (vagus) systems
and non-autonomic innervation. It has long been known that
the taste, smell and even sight of food can trigger insulin
release, referred to as the cephalic phase of insulin secretion
[16]. A number of studies have shown that altering neural
metabolism experimentally can change islet hormone release,
including insulin [17]. Stimulation of the vagus nerve increases
pancreatic insulin output [18–20], whereas the net effect of
splanchnic nerve stimulation is to reduce insulin and increase
glucagon output [21]. A number of studies using retrograde
tracers such as modified pseudorabies virus injected into the
pancreas have mapped out the central brain connections to
pancreas, including areas that contain fuel-sensing neurones
such as the dorsal vagal complex in the brain stem and key
hypothalamic nuclei (reviewed in Ref. [17]).
Supporting a role for direct brain glucose sensing in the
facilitation of insulin release, elegant studies in catheterized rats
have shown that a small glucose bolus (insufficient to result in
a systemic rise in glucose) given directly into the carotid artery
directed towards brain induced a peripheral insulin response.
This was associated with activation of the hypothalamic
paraventricular and arcuate nuclei. [22,23]. Recent data
suggest that, in addition to effects on insulin secretion, brain
glucose sensing acting via pancreatic innervation may control
β-cell mass [24].
Brain Glucose Sensing and Feeding/Energy
Homeostasis
Although hypoglycaemia is a very potent stimulator of appetite,
the role of brain glucose sensing at more physiological glucose
levels remains unclear. Over 50 years ago, the glucostatic theory
postulated that blood glucose levels were a physiological deter-
minant of feeding. Suggested mechanisms were either in the
initiation of eating, with small dips in blood glucose appearing
to precede feeding and/or by the rise in blood glucose induced
by feeding then acting as a satiety/meal termination signal.
Energy balance depends on intake but also on energy
expenditure. Like other nutrients, glucose may also act centrally
to generate thermogenesis [25], perhaps dependent on brain
GLUT2-mediated glucose sensing (see below).
Mechanisms of Brain Glucose Sensing
For all of the above processes to occur, brain nutrient sensors
need to be able to detect rapidly and accurately changes in
blood glucose, presumably by detecting corresponding changes
in ambient glucose within the brain. Glucose-sensing neurones
were first described in the 1960s, with two populations
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of neurones being either activated by glucose (glucose-
excited – GE) or inhibited (originally referred to as glucose-
sensitive but now globally labelled as glucose-inhibited – GI)
[26,27]. GE and GI neurones have been identified in an
increasing number of brain areas. Within the hypothalamus,
both GE and GI neurons are found in the arcuate and
paraventricular nuclei, with GI also particularly in the lateral
hypothalamus and GE in the VMN [28]. GE and GI neurones
are also found in the nucleus tracts solitarius and area postrema
in the brain stem [29,30]. It appears probable that different
subgroups of GE and GI neurones exist, with some operating
at higher glucose values (‘high GE’ and ‘high GI’ neurones).
Although most work has focused on the metabolic-sensing
potential of neurones, it is clear that there is a close metabolic
coupling between surrounding glial cells and neurones [31].
This may be important in glucose sensing also, for example
with glucose being taken up by astrocytes and metabolized to
lactate, which is then transported across into neurones. In this
situation, glucose-sensing neurones would be responding to
lactate rather than glucose per se.
There are probably a number of mechanisms by which GE
and GI neurones respond to glucose and/or other fuels such as
lactate. In broad terms, most postulated sensing mechanisms
are ‘metabolic’, that is they depend on glucose-entering cells and
being metabolized, with fuel sensing then detecting the process
or products of that metabolism. Alternatively, sensing may use
non-metabolic signals. For example, glucose sensing using the
electrogenic signal generated by active glucose transport by
sodium-coupled glucose co-transporter (SGLT) 1/3 has been
described [32]. It is also possible that glucose sensing may occur
without glucose entry into cells – for example by tandem pore
potassium channels or perhaps even by taste receptors [33]. In
this review, we have described briefly some of the metabolic
sensors postulated to be important.
A number of research groups have examined the analogies
between pancreatic β-cell and brain glucose sensing. Peculiar
features of the β-cell that allow it to detect glucose (at least in
the canonical pathway) include ATP-gated potassium (KATP)
channels, the low-affinity glucose transporter GLUT2 and the
low-affinity hexokinase, glucokinase.
The role of brain glucokinase is described later in this review.
KATP channels are distributed widely in the brain, including in
glucose-sensing areas. This wide distribution suggests that their
role is broader than nutrient sensing – perhaps in protection
of neurones against injurious insults. They have, however, been
implicated in brain glucose sensing. Using a pharmacological
approach, closing KATP channels by brain infusion of sulpho-
nylureas attenuated responses to hypoglycaemia [34] and brain
delivery of KATP channel openers increased hypoglycaemic
counter-regulatory responses [35]. Mice deficient for the
Kir6.2 subunit of KATP channels showed reduced responses in
glucose-sensing neurones in the ventromedial hypothalamus
and defective glucagon (but not adrenaline) responses to both
hypoglycaemia and brain glucopenia. Of note, isolated islets
from these mice studied ex vivo showed glucagon responses to
glucose similar to those of wild-type mice [36].
Data suggest that hypothalamic levels of the inhibitory
neurotransmitter γ -aminobutyric acid (GABA) may act
downstream of KATP channels to modulate glucagon responses
to hypoglycaemia. Closing or opening KATP channels in the
VMN resulted in increased or decreased VMN GABA levels,
respectively, associated with suppression or amplification
of glucagon and other counter-regulatory responses to
hypoglycaemia [37,38]. Microperfusion of glucose into the
VMN of rats suppressed glucagon and adrenaline responses to
hypoglycaemia and altered VMN GABA with these effects of
VMH glucose being blocked by GABA A antagonism [39].
The low-affinity transporter, GLUT2, has also been identified
within brain regions. Using an elegant transgenic mouse
model combining GLUT2 knockout (with re-expression of
the alternative transporter GLUT1 in pancreatic β-cells to
maintain insulin secretion), Thorens’ group found reduced
glucagon responses to glucoprivation [40]. Glucagon responses
to low glucose were restored by brain re-expression of GLUT2,
but interestingly in glial rather than neuronal cells [41].
Parenthetically, the insulin-responsive transporter GLUT 4
and indeed insulin receptors have been identified in VMN
GE and GI neurones although the significance for metabolic
homeostasis remains to be fully determined [42].
A number of ‘non-β-cell’ sensing mechanisms dependent on
intracellular metabolism of glucose have also been implicated
in brain glucose sensing. Perhaps the best characterized is the
cellular energy sensor AMP-activated protein kinase (AMPK),
which is found widely in the brain, including in glucose-
responsive cells [43]. Targeted genetic knockdown of AMPK
in rat VMN suppressed glucagon responses to hypoglycaemia,
whereas pharmacological activation of VMN AMPK amplified
responses in rats with impaired counter-regulation [44,45].
Distribution of Glucokinase in the Brain
Approaches taken to identify the presence and distribution of
glucokinase in the brain have largely looked for messenger
RNA (mRNA) (RT-PCR and in situ hybridization) and
activity assays measuring low-affinity glucose phosphorylation
activity. Identifying glucokinase protein reliably has been more
challenging, perhaps because of low levels of expression.
Studies using transgenic mice with human growth hormone
expressed under the glucokinase promotor confirmed glucok-
inase expression in the brain, but detailed characterization of
glucokinase-containing neurones was limited by a relatively
low resolution [46]. This was also true for in situ hybridiza-
tion studies with or without dual immunohistochemistry and
RT-PCR work that identified some dual staining with candi-
date neuropeptides. However, full characterization was difficult
[47,48]. Intriguingly, glucokinase mRNA has also been identi-
fied in tanycytes, raising the possibility that this population of
glial cells are involved in metabolic sensing [49].
Stanley et al. have recently reported a comprehensive char-
acterization of glucokinase-expressing cells in the brain [50].
To do so, they created a mouse line expressing cre-recombinase
under control of the neuronal glucokinase promotor and
crossed mice with a line expressing an EGFP-tagged ribosomal
construct. This allowed them to examine the distribution of
glucokinase in the brain and also to perform transcriptional
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profiling of glucokinase-expressing cells. Using this model, glu-
cokinase was identified in hypothalamic and limbic regions of
the brain, with many of the areas having been identified (albeit
with less resolution) by previous studies. They also examined
and quantified responses to either 2DG or glucose and identified
activation measured by c-fos expression in glucokinase cells.
Perhaps the most insightful part of their work came
from transcriptional profiling. Hypothalamic enrichment was
identified for a number of neuropeptides that might have
been predicted to be found in glucose-sensing cells [orexin,
pro-opiomelanocortin (POMC), neuropeptide Y (NPY) and
agouti-related peptide (AGRP)]. Dual immunohistochemistry
confirmed that glucokinase was found in a subset of
the corresponding cell populations with 36% of lateral
hypothalamic orexin neurones (GI), 20% of POMC (GE)
and 28% of NPY/AGRP (GI) neurones. Importantly, this
emphasizes that there is likely to be heterogeneity within
these cellular populations with some either using different
fuel-sensing apparatus or perhaps not possessing the ability to
sense glucose directly. Also of note, approximately one third
of glucokinase-expressing cells in the brain identified by this
approach were glial rather than neuronal.
There was a marked enrichment in growth-hormone-
releasing hormone (GHRH)-containing neurones. Subsequent
dual immunohistochemistry and patch clamp studies con-
firmed that the majority of GHRH neurones contained glucok-
inase and that they were GI with activity increasing as blood
glucose fell. Growth hormone is a part of the counter-regulatory
hormonal response to hypoglycaemia, and prior to this work,
the mechanisms by which this was triggered were unclear. It
appears probable that this occurs via direct glucose sensing by
GHRH neurones utilizing glucokinase.
A paradox remains for β-cell-type adaptations such as glu-
cokinase and GLUT2, namely why brain would use low-affinity
mechanisms. Brain glucose values undoubtedly vary from
region to region, but are probably 10 to 30% of those observed
in the circulation. If so, one would predict that glucokinase
and GLUT2 would be largely inactive at ambient glucose levels,
and certainly so during hypoglycaemia. The question remains
unresolved. Although brain glucose sensors are clustered close
to circumventricular organs such as the median eminence
(hypothalamus) and area postrema (brain stem) where the
blood–brain barrier is deficient, there is currently little evidence
that this alters ambient glucose levels in the sensing areas per se.
Altering Brain Glucokinase Activity
Experimentally
Ex vivo, a number of studies using fresh brain slices and/or pri-
mary hypothalamic cultures have identified that glucokinase is
part of the sensing mechanism for at least a subset of GE and GI
hypothalamic neurones [42,51–53]. Knockdown of glucoki-
nase by interfering RNA in VMN preparations largely abolished
GE and GI glucose-sensing activities, whereas glucokinase
activation amplified both GE and GI responses. Extending
this work in vivo, infusion of GK activators into the VMN
reduced glucagon response to hypoglycaemia in rats. Similarly,
inhibiting glucokinase with alloxan or short hairpin RNA
(shRNA) knockdown increased responses – predominantly
adrenaline – to hypoglycaemic challenges [54]. Outside the
hypothalamus, glucokinase-dependent glucose sensing was also
identified in the medial amygdala nucleus with a population of
glucokinase-containing sensing neurones utilizing urocortin-
mediated connections to the basomedial hypothalamus exert-
ing a control loop to increase or decrease counter-regulatory
responses to hypoglycaemia [55]. Using third ventricle infusion
of pharmacological inhibitors of glucokinase, we were able to
stimulate feeding responses to glucoprivation [56]. This was
associated with activation of NPY and orexigenic cells [57].
One study has examined counter-regulatory hormone
responses in humans with glucokinase mutations leading to
‘MODY-2’ monogenic diabetes [58]. Glucagon responses to
hypoglycaemia were increased, although it is unclear whether
this was because of pancreatic or brain glucokinase in subjects
with a whole-body glucokinase activity alteration.
Interesting data examining the effect of the proapoptotic
protein, BCl-associated death promotor (BAD) may also reflect
a role for brain glucokinase in responses to hypoglycaemia.
In the β-cell, BAD alters glucose levels by altering insulin
secretion by at least two different mechanisms depending on
its phosphorylation status – an interaction with glucokinase
and by its proapoptotic actions. Acute genetic knockdown of
BAD in the brain impaired the glucagon response to systemic
glucoprivation in mice, although whether this was mediated
through altered brain GK activity remains unclear [59].
We have also examined whether brain glucokinase-mediated
glucose sensing is important in mediating insulin responses to
a rise in blood glucose [60]. We used intravenous glucose
tolerance tests in rats with delivery of test substances into
the base of the third ventricle. We first examined delivery
of glucose, reasoning that if brain sensing of glucose was
important for dealing with a systemic glucose load, that we
would see an increased efficiency of dealing with glucose
challenge. In keeping with this, we found that glucose handling
was improved, particularly early-phase insulin over the first
10 min after intravenous glucose delivery. Consistent with a
role for brain glucose sensing in facilitating insulin release,
early-phase insulin release was stimulated.
We then examined whether brain glucokinase contributed
to this observation, delivering glucokinase inhibitors into
the third ventricle of rats prior to and during intravenous
glucose bolus delivery. Again, in keeping with our hypothesis,
intracerebroventricular glucosamine or mannoheptulose, an
alternative inhibitor, reduced glucose tolerance associated with
a decrease in insulin release over the first few minutes.
We have also examined the effects of pharmacological
inhibition of brain glucokinase on feeding reponses. In keeping
with a role for brain glucokinase in central glucose sensing,
central delivery of glucosamine or mannoheptulose rapidly
triggered robust feeding responses in rats [56].
Changes in Glucose Sensing in Diabetes
and Obesity?
A subset of patients with diabetes – particularly but not
only those with type 1 diabetes – develop deficiencies in
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their counter-regulatory-defensive responses in the face of
falling blood glucose. Neurohumoral responses are delayed
and diminished, and the associated warning symptoms are
also reduced. This altered physiology is associated clinically
with a significantly increased risk of suffering from severe
hypoglycaemia. Given the evidence for brain glucose sensing
playing a key role in triggering counter-regulation (as
discussed earlier), the unproven assumption is that this loss
of counter-regulation or loss of warning symptoms is a
consequence of altered glucose sensing and/or adaptations
in the circuitry occurring very close to the site of glucose
sensing.
The exact mechanisms remain to be fully determined and
it is unclear whether glucokinase may play a role in this. For
example, in juvenile rats, glucokinase expression within the
VMN was increased after hypoglycaemia and associated with a
shift in glucose responsiveness of GE neurons [61]. In contrast,
we found no change in hypothalamic glucokinase expression
following recurrent hypoglycaemia in rat brains, but rather an
increase in hexokinase expression [62]. Regardless of whether
involved in the pathoaetiology, it is possible that targeting
brain glucokinase might alter counter-regulatory responses
to hypoglycaemia for good or bad. For example, one might
predict a theoretical risk of reducing counter-regulation with
glucokinase activation, a concern given that a number of
pharmaceutical agents are in development for treating diabetes
through activation of peripheral (β-cell and/or liver) GK.
Some reassurance comes from studies in humans in which a
single dose of a glucokinase activator had no obvious central
effect on counter-regulatory responses to hypoglycaemia, with
suppressed glucagon responses probably related to a local
paracrine effect from altered insulin levels [63].
There is no compelling evidence for an effect of brain
glucokinase on appetite and energy balance. As described above,
we found that experimental inhibition of glucokinase in the
rat brain stimulated glucoprivic feeding [56], but it is not clear
how much overlap there is (if any) between feeding in response
to a lack of glucose (a potential emergency situation) and
general appetitive behaviour. We await more specific tools to
manipulate brain glucokinase – perhaps targeted conditional
transgenic murine models – to examine in a more definitive
way whether brain glucokinase plays a broader role in energy
metabolism.
Summary: Brain Glucokinase and Glucose
Sensing
In summary, it appears probable that brain glucokinase is
present in a variety of glucose-sensing cells – possibly both
glial and neuronal. Intriguingly, it appears that this includes
both GE cells – analogous to the pancreatic β-cell – but also
GI neurones suggesting other downstream-mediating effects.
It is tempting to speculate that GI neurones may be broadly
analogous to pancreatic α-cells, but perhaps safest to assume
that this all illustrates that brain glucose sensing shares some,
but not all, features of those mechanisms identified elsewhere
in the body.
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